| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 173.0 | 160.0 |
| Profit before tax | -127.0 | -179.0 |
| Net income | -118.0 | -180.0 |
| EPS (diluted, $ a share) | $-1.16 | $-1.81 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +8.1% |
|---|---|
| Operating margin | -63.6% |
10-Q filed with the SEC, NASDAQ: RARE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ultragenyx Pharmaceutical Inc.: key numbers
- Share price
- $16.70Close, Nov 17
- Market cap
- $1.7B
- Shares outstanding
- 101.92MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ultragenyx Pharmaceutical Inc.
All →Ultragenyx Pharmaceutical Financial Results
Ultragenyx reported Q3 2026 total revenue of $173 million and a net loss of $118 million, while announcing a major restructuring plan to reduce its workforce by 20%. The company also confirmed the sale of two Priority Review Vouchers for $413 million and reaffirmed its 2026 revenue guidance and 2027 profitability targets.
- Term
- Q3 2026
“We received two BLA approvals from the FDA within one month for our first gene therapy treatments and the launches are progressing well with growing demand for these products. With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.”
Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx
Ultragenyx Pharmaceutical CFO Howard Horn Sells $108K of Stock
Howard Horn, CFO, sold 7,066 shares of Ultragenyx Pharmaceutical Inc. at $15.27 a share, worth $108K in total on Oct 15, 2026. Shares held after the trade: 89,229 (-7.3%).
- Value
- $108K
- Shares
- 7,066
- Price
- $15.27
- Role
- CFO
- Holding change
- -7.3%
- Trade date
- Oct 15, 2026
Ultragenyx Pharmaceutical Court & Legal Update
Ultragenyx and Baylor Research Institute entered into a settlement agreement with Navinta LLC to resolve patent litigation regarding DOJOLVI® (triheptanoin). Under the agreement, Navinta is granted a non-exclusive, royalty-free license to market a generic version of the drug starting January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted.
- Counterparty
- Navinta LLC
Ultragenyx Pharmaceutical Divestiture for $203M
Ultragenyx Pharmaceutical Inc. entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million in cash. The PRV was recently awarded by the FDA following the approval of FAYUVI (UX111) for the treatment of Sanfilippo syndrome Type A. The transaction is subject to customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino Act.
- Value
- $203M
Ultragenyx Pharmaceutical Divestiture for $210M
Ultragenyx Pharmaceutical Inc. entered into an asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million in cash. The PRV was recently awarded by the FDA following the approval of GENGLYCOS for the treatment of glycogen storage disease type Ia. Under a prior agreement, the company will pay 20% of the gross proceeds from this sale to the NIH.
- Value
- $210M
Ultragenyx Pharmaceutical Regulatory Approval
The FDA has granted standard full approval for Ultragenyx's FAYUVI (rebisufligene etisparvovec-hopf), the first-ever approved treatment for Sanfilippo syndrome Type A (MPS IIIA). This marks the company's second gene therapy approval and resulted in the receipt of a Priority Review Voucher.